

Anti-CTLA-8/IL-17a Antibody (Secukinumab)

Introduction

Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is a first-in-class anti-IL-17 agent being investigated in plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.

Product parameters

Alternative Names	Cosentyx, AIN457
Target Accession	Q16552
Target	CTLA-8 / IL-17a
CAS number	1229022-83-6
Molecular Weight	147.82 kDa
Host	CHO
Reactivity	Human, Cynomolgus, Rhesus
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL 17A FC at 2 ug/mL can bind Anti-CTLA-8/IL-17a Antibody (Secukinumab), EC50=0.04266 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

